ADVANCE for Executive Insight 1 ADVANCE for Executive Insight

VPAP COPD
NONINVASIVE VENTILATION
Is the cost of
COPD readmissions
becoming a problem?
Improve outcomes with the first NIV device
FDA-cleared specifically to treat COPD. 1
Research shows that post-discharge NIV therapy for
COPD patients can reduce admissions and minimize
hospital costs, reduce recurrence of acute hypercapnic
respiratory failure following an initial event by up to
two-thirds in the first 30 days, and provide patients with
significant quality of life benefits. 2-5 Wouldn’t you like to
offer your patients a better chance at a brighter future?
VPAP COPD with H5i humidifier and
ClimateLine MAX Oxy
Learn more and request a free guide at
ResMed.com/COPD.
1 The VPAP COPD is indicated to provide noninvasive ventilation for patients weighing more than 30 lbs (13 kg) with respiratory insufficiency such as that associated with hypercapnic chronic obstructive pulmonary disease (COPD)
or obstructive sleep apnea (OSA). 2 Tuggey et al. Thorax 2003 3 Cheung et al. Int J Tubercul Lung Dis 2010 4 Tsolaki et al. Respir Med 2008 5 Duiverman et al. Thorax 2008 ©2013 ResMed.
ADVANCE for Executive Insight
7